[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transplant-failure-liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transplant-failure-liver":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,84,116,142,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100589159","changes-in-glucose-tolerance-in-patients-with-cirrhosis-peri-liver-transplant-100589159",false,"NCT06950788","Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant","Inclusion Criteria:\n\n* Patients presenting to liver transplant clinic with a diagnosis of cirrhosis.\n* Age \\>18 yrs.\n* Ability to understand and sign written consent form, or have a legally-authorized representative or proxy who can be approached for consent\n\nExclusion Criteria:\n\n* Patients without consent\n* Patients with implantable cardioverter defibrillator devices or automated implantable cardioverter defibrillator devices will be excluded from the bio-electrical impedance analysis portion of the measurements.\n* Patients with unremovable electrical medical devices or devices that cannot turn off will be excluded from the bio-electrical impedance analysis measurements\n* Pregnant patients\n* Incarcerated patients\n* Patients with a history of type 2 diabetes mellitus diagnosed \\> 5 years ago will be excluded from the Oral Glucose Tolerance Test portion of the study","ALL","18 Years","75 Years",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation.\n\nThe question being addressed is: can laboratory work, anthropometric tests, functional tests, imaging, and advanced measurements such as wrist actigraphy, continuous glucose monitoring, or oral glucose tolerance testing predict the development of diabetes after liver transplant?\n\nParticipants will be asked to periodically participate in wearing a continuous glucose monitor and wrist actigraph and obtain an oral glucose tolerance test both before and after liver transplant.",[24,25,26,27],"Cirrhosis, Liver","Diabetes Mellitus Risk","Transplant; Failure, Liver","Transplant-Related Disorder",[29,30,31,32],"Cirrhosis","Post-transplant diabetes","New-onset diabetes after transplant","Liver transplantation","RECRUITING","2026-05-01",{"date":36,"type":37},"2026-05-07","ACTUAL",{"date":39,"type":37},"2024-03-12",{"date":41,"type":20},"2031-01",{"name":43,"class":44},"University of Chicago","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":45},"100486356","leveraging-technology-to-improve-medication-adherence-in-youth-with-kidney-or-liver-transplant-100486356","NCT05613010","Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant","Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients: A Micro-Randomized Trial","Inclusion Criteria:\n\n* Adolescents and young adults (13-25 years old) who underwent kidney or liver transplantation at least 6 months prior to enrollment\n* Currently prescribed tacrolimus or sirolimus.\n\nExclusion Criteria:\n\n* Currently receiving dialysis\n* Hospitalized for duration of study\n* Significant developmental or cognitive delay\n* No access to a mobile device that supports text messaging\n* Decline to use electronic pill box to monitor daily medication adherence\n* Non-English speaking\n* If a participant meets inclusion criteria, enrolls in the study, and experiences graft failure potentially leading to dialysis in the case of kidney transplant recipients, the participant will be given the option to continue in the study if they remain on tacrolimus or sirolimus.","13 Years","25 Years",{"count":56,"type":20},65,"INTERVENTIONAL",[59],"NA","Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation? The investigators' mobile technology intervention uses real-time electronic pillbox-assessed dose timing and text message prompts to address antirejection medication nonadherence when nonadherence is detected.",[62,26,63,64,65],"Transplant;Failure,Kidney","Adherence, Medication","Adherence, Patient","Adherence, Treatment",[67,68,69,70,71,72,73,74],"kidney transplant","liver transplant","medication adherence","medication nonadherence","compliance","mobile health","mobile phone","technology","2026-04-09",{"date":77,"type":37},"2026-04-13",{"date":79,"type":37},"2024-03-19",{"date":81,"type":20},"2026-11-30",{"name":83,"class":44},"Johns Hopkins University",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":57,"phases":94,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":45},"100309634","abdominal-wall-transplant-100309634","NCT03310905","Abdominal Wall Transplant","Abdominal Wall Transplantation for the Reconstruction of Abdominal Wall Defects as Adjunct to Abdominal Solid Organ Transplantation","Inclusion Criteria:\n\n* Candidates between 18-65 years old\n* Willingness and legal ability to give consent\n* Abdominal Wall in combination with another organ transplant: they must be eligible for the non-vascularized composite allograft organ transplant at Duke\n\nExclusion Criteria:\n\n* Malignancy at evaluation or history of malignancy that precludes transplantation\n* Pregnancy: Women who are of childbearing potential must have a negative serum pregnancy test within 48 hours of transplant and agree to use reliable contraception with two contraceptive methods for a minimum of 2 years following abdominal wall transplantation. Subjects seeking to become pregnant following 2 years will be made aware during the consent process that the effect of pregnancy on the transplanted abdominal wall and vice versa is unknown.\n* Medical exclusion criteria for general anesthesia\n* Ongoing substance abuse or history of untreated substance abuse","65 Years",{"count":93,"type":20},5,[59],"The purpose of this protocol is to determine the safety and efficacy of abdominal wall transplantation as a treatment for the reconstruction of abdominal wall defects. Abdominal wall transplantation may be performed alone or in combination with another transplant.",[62,26,97,98,99,100,101],"Transplant; Failure, Bowel","Abdominal Wall Defect","Abdominal Wall Fistula","Abdominal Wall Hernia","Abdominal Wall Injury",[103,104,105,106],"Research","Transplant","Abdominal Wall","Hernia","2026-01-05",{"date":109,"type":37},"2026-01-07",{"date":111,"type":37},"2018-05-01",{"date":113,"type":20},"2028-06-01",{"name":115,"class":44},"Duke University",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":15,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":57,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100546573","ease-sot-pilot-study-100546573","NCT06396702","EASE-SOT Pilot Study","Emotion And Symptom-focused Engagement (EASE) Intervention for the Management of Emotional and Physical Symptoms Among Solid Organ Transplant Recipients-pilot Study","Inclusion Criteria:\n\n* Participants consented pre-transplant: Potential transplant recipients who are listed on the waitlist and are identified by pre-transplant staff, recipients who have a living donor arranged (pertaining to kidney and liver recipients), participants currently completely pre-transplant prehabilitation (pertaining to lung and heart recipients), or those who are on the top of their respective organ transplant waitlists.\n* Participants consented post-transplant: Incident kidney, kidney-pancreas, liver, lung, or heart transplant recipients identified during index transplant hospital admission at the inpatient transplant unit of the Ajmera Transplant Centre at Toronto General Hospital\n\nExclusion Criteria:\n\n* Patients in ICU.\n* Patients who are clinically unstable, have delirium or other severe mental health concern requiring psychiatric treatment - assessed by clinical team.\n* Non-English speaking patients.\n* Severe cognitive impairment as assessed by the recruitment and\u002For research team. This will be determined through communication with the organ transplant teams and by checking the patient's medical charts. If no cognitive impairment is indicated by the patients organ transplant team or is documented in their medical chart, the patient will be assessed to have no cognitive impairment.\n* Unwilling or unable to provide informed consent.","19 Years",{"count":125,"type":20},120,[59],"Many transplant recipients may experience physical and emotional symptoms, such as anxiety, fatigue, sleep problems, pain, etc. Often, these symptoms are not reported or managed well, and can affect a patient's quality-of-life. Transplant recipients are grateful for the \"gift of life\" but physical and emotional symptoms reduce their quality-of-life. Transplant recipients and caregivers have felt unprepared for the ongoing symptoms and reduced quality-of-life post-transplant.\n\nOne way of monitoring and managing these symptoms is using the Emotion And Symptom-focused Engagement (EASE) intervention. EASE was originally developed for patients with acute leukemia and has begun to be adapted to help monitor and manage physical and emotional symptoms for organ transplant recipients.\n\nEASE is comprised of two components:\n\n1. Psychological - 8 supportive counselling sessions delivered by mental health clinicians to address concerns about mental health, losses from organ failure, coping with a transplant, experiences with living on the brink of death for a prolonged period of time, etc.\n2. Physical - Regular assessments of physical symptoms using questionnaires and referral to healthcare professionals for symptom management as necessary.\n\nEASE uses questionnaires, also called patient reported outcome measures (PROMs), for symptom assessment and monitoring. PROMs measure symptom severity, similarly to how bloodwork measures organ functioning. PROMs, as part of EASE, will ask recipients questions and help identify relevant physical, emotional, and social symptoms to enhance their care.\n\nWith the help of specialists, patients, and support from the Kidney Foundation of Canada, our team has begun to adapt the EASE intervention for transplant recipients. In order to finalize the adaptation of the EASE intervention for use in a routine transplant clinic, we are launching a pre-pilot study to gain real-life experience from managing symptoms of SOT recipients with the use of EASE-SOT.",[62,129,26,130,131],"Transplant; Failure, Heart","Transplant; Failure, Pancreas","Transplant; Failure, Lung(S)","NOT_YET_RECRUITING","2024-04-29",{"date":135,"type":37},"2024-05-02",{"date":137,"type":20},"2024-05",{"date":139,"type":20},"2027-08",{"name":141,"class":44},"University Health Network, Toronto",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":57,"phases":153,"briefSummary":154,"conditions":155,"keywords":161,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100512344","liver-transplantation-after-ex-vivo-liver-perfusion-100512344","NCT05951231","Liver Transplantation After ex Vivo Liver Perfusion","Liver Transplantation After ex Vivo Liver Perfusion - The EVOLVE Study","EVOLVE","Inclusion Criteria:\n\n* Signed informed consent\n* ≥ 18 years\n* Indication for liver transplantation (one criteria must be met):\n* Colorectal cancer patients who have received 1st and 2nd line chemotherapy where the treatment has been stopped due to progression or toxicity and the patient is not eligible for SECA-2 (Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases) study.\n* Hepatocellular carcinoma patients who are not suitable for standard liver transplantation, liver resection or local treatment (Transarterial Chemoembolisation or Selective internal radiotherapy). The patients must have progression or intolerance (toxicity) for immune checkpoint inhibitors or 1st line treatment.\n* Cholangiocarcinoma patients who have progression or intolerance to first-line chemotherapy.\n* Benign liver disease with urgent need for transplantation within months, but no regular graft is available.\n* Life expectancy ≤ 6 months\n* Willing, able and expected cooperation to attend follow-up examinations\n* Patients who have a need for liver transplantation but cannot participate in other transplant studies or participation in another clinical trial with randomization to liver transplantation.\n\nFor malignant disease the following criteria must be met:\n\n* Good performance status assessed at the discretion of the treating physician.\n* ECOG (Eastern Cooperative Oncology Group) 0 or 1\n* Satisfactory blood tests\n\n  * Hemoglobin \\>8 g\u002Fdl\n  * Neutrophiles \\>1.0 (after any Granulocyte colony-stimulating factor)\n  * Platelets \\>75\n  * Bilirubin \\\u003C1.5 x upper normal level\n  * ASAT (Aspartate aminotransferase), ALAT (alanine aminotransferase) \\\u003C5 x upper normal level\n  * Albumin above lower normal level.\n\nExclusion Criteria:\n\n* Already listed for ordinary Ltx with expectance of getting offered a regular liver graft within a reasonable time-frame.\n* Patients included in the control arm of the SECA-3 study or the Excalibur studies except for the Ltx arm of the Excalibur I study.\n* Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial.\n* Any reason why, in the opinion of the investigator, the patient should not participate.","100 Years",{"count":152,"type":20},22,[59],"Today, it is difficult to predict liver function after transplantation and therefore livers where poor function is assumed (marginal livers) become discarded. The study aim is to increase the number of available donor livers, especially for liver cancer patients, by pre-treating and testing marginal ones (extended criteria donor (ECD) livers) liver on a liver perfusion machine. A liver perfusion machine can simulate liver transplantation and enables functional\u002Fquality testing before transplantation. The machine will hopefully also make marginal livers more functional by reducing ischemia- \\& reperfusion injury. A marginal donor liver is perfused ex situ with oxygenated blood from a blood donor on a machine. The liver can be tested here for function using internationally recognized criteria. At the same time, the investigators will carry out analyzes with microdialysis which can give a better picture of organ function and damage. Additionally, various samples of the liver and perfusate will be collected. Liver that achieves criteria for transplantation will be offered to the recipient.",[156,26,157,158,104,159,160],"Liver Transplant; Complications","Transplant Dysfunction","Transplant; Complication, Rejection","Liver Metastases","Liver Cancer",[162,163,164,165,166,167,168],"Liver","Transplantation","Perfusion","Dual-end-ischemic Hypothermic Oxygenated Perfusion","Normothermic Machine Perfusion","Controlled Oxygenated Rewarming","Microdialysis","2023-10-31",{"date":171,"type":37},"2023-11-01",{"date":173,"type":20},"2024-02",{"date":175,"type":20},"2029-02",{"name":177,"class":44},"Oslo University Hospital",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":185,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":45},"100500203","single-center-prospective-study-of-non-invasive-methods-for-the-diagnosis-of-postoperative-complications-in-liver-transplant-recipients-100500203","NCT05793203","Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients","ElastOLT","Inclusion Criteria:\n\n* Patients eligible for liver transplantation following National and International Guidelines\n\nExclusion Criteria:\n\n* No agreement or inability to give informed consent\n\n  * Re-transplant patients\n  * Liver transplant in fulminant hepatitis",{"count":186,"type":20},100,"A lot of different early and late complications may occur after liver transplantation. They could be related to surgical procedure, to infectious diseases or immuno-mediated diseases (acute cellular rejection, ACR). Almost all of those complications are characterized by an elevation in liver enzymes (ALT, AST and GGT) and a decline of liver function tests (serum bilirubin and INR increase) possibly leading to early allograft disfunction (EAD). In this scenario there is a lack of biomarker that could predict the development of ACR and\u002For EAD.\n\nThe aim of this study is to explore the prognostic role of non-invasive instrumental and biological marker in the early post-transplant phase.",[189,26,190],"Rejection Acute Hepatic","Liver Dysfunction","2023-03-20",{"date":193,"type":37},"2023-03-31",{"date":195,"type":37},"2020-07-06",{"date":197,"type":20},"2027-12-31",{"name":199,"class":44},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]